

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Padeliporfin for treating localised prostate cancer**

**Batch 46**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A consultee stated that this technology may reduce age-related inequalities in access to radical surgery or radiotherapy for localised prostate cancer. The consultee noted that people aged over 80 have a statistically significantly lower rate of access to surgery or radiotherapy than the average in England.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee is unable to make recommendations about existing treatment options, such as surgery or radiotherapy. It may need to discuss whether some people, for example older people, have difficulties in accessing the current treatment options in the NHS. The Committee would consider the reasons for any inequality in access to treatment, and whether it can make recommendations about the use of padeliporfin that reduce this inequality.

It should be noted that the main comparator for padeliporfin is active surveillance. Thus, for most of the licensed population, it may not be relevant to discuss access to alternative active therapies such as surgery.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

**Approved by Associate Director (name):** Elisabeth George

**Date:** 20/12/2017